RxDoctor Payments Data

Rujul Patel, DO

Cardiovascular Disease · Bethlehem, PANPI 1831328871

Payments from drug & device makers

$615in general payments, 2019–2025

Across 7 payments — averaging $87.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$145
  • Amgen$115
  • Novo Nordisk$115
  • Biohaven Pharmaceuticals, Inc.$113
  • Johnson & Johnson$88
  • Boston Scientific$38

What the payments were for

  • Food & beverage$615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$615 in reported general payments places this provider in the 30th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$201,769
Medicare patients
1,329
Services billed
6,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban427$487,165
XareltoRivaroxaban116$134,057
EntrestoSacubitril/Valsartan36$38,652
Repatha SureclickEvolocumab48$36,663
BrilintaTicagrelor17$15,283
Dofetilide28$12,184
VascepaIcosapent Ethyl23$11,251
Droxidopa13$9,492
Rosuvastatin Calcium479$6,828
Metoprolol Succinate452$6,475
Amiodarone Hcl106$5,872
Dabigatran EtexilateDabigatran Etexilate Mesylate13$5,548
Icosapent Ethyl23$5,188
Atorvastatin Calcium317$3,950
Potassium Chloride148$3,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$88$134,057116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →